Comparative Pharmacology
Head-to-head clinical analysis: LOMOTIL versus LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOMOTIL versus LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE.
LOMOTIL vs LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diphenoxylate is a meperidine congener that acts as an opioid receptor agonist, inhibiting gastrointestinal motility and prolonging transit time; atropine is added to discourage abuse at high doses.
Loperamide binds to mu-opioid receptors in the intestinal wall, reducing peristalsis and increasing intestinal transit time, allowing for greater absorption of water and electrolytes. It also decreases fecal volume and increases stool consistency. Simethicone reduces the surface tension of gas bubbles in the stomach and intestines, facilitating their coalescence and passage via belching or flatulence.
Adults: 2 tablets (2.5 mg diphenoxylate/0.025 mg atropine) orally four times daily until control of diarrhea is achieved; maintenance dose is 2 tablets once or twice daily. Maximum dose: 8 tablets (20 mg diphenoxylate) per day.
2 tablets (4 mg loperamide hydrochloride / 250 mg simethicone) orally after first loose stool, then 1 tablet (2 mg/125 mg) after each subsequent loose stool; maximum 4 tablets (8 mg/500 mg) per day for no more than 2 days.
None Documented
None Documented
Diphenoxylate: 2.5-3.5 hours; Difenoxin (active metabolite): 12-24 hours. Clinically, antidiarrheal effect is prolonged due to metabolite accumulation.
Loperamide: 7-14 hours (mean 10.8 hours) in healthy adults; prolonged to 18-26 hours in hepatic impairment.
Primarily renal (50-70% as metabolites, <5% unchanged) and fecal (30-50% via biliary excretion).
Loperamide: 97% fecal, 3% renal. Simethicone: excreted unchanged in feces.
Category C
Category A/B
Antidiarrheal
Antidiarrheal